Press Releases & Media Statements

Date Title  
Toggle Summary AveXis Statement on Changes to Senior Leadership Team
AveXis shares Page Bouchard, DVM named Senior Vice President of Research and Chief Scientific Officer, AveXis, effective August 5, 2019. Dr Bouchard is a 27 year industry veteran with experience in well over 100 Investigational New Drug programs and dozens of New Drug Application/Biologics License
AveXis Statement on Changes to Senior Leadership Team
AveXis shares Page Bouchard, DVM named Senior Vice President of Research and Chief Scientific Officer, AveXis, effective August 5, 2019. Dr Bouchard is a 27 year industry veteran with experience in well over 100 Investigational New Drug programs and dozens of New Drug Application/Biologics License
Toggle Summary Novartis stands behind Zolgensma® (onasemnogene abeparvovec- xioi) for the treatment of children less than 2 years of age with spinal muscular atrophy
Basel, August 6, 2019 – Today the FDA released a statement addressing data integrity issues with the Biologics License Application (BLA) for Zolgensma® (onasemnogene abeparvovec-xioi). First and foremost, we are fully confident in the safety, quality and efficacy of Zolgensma.
Novartis stands behind Zolgensma® (onasemnogene abeparvovec- xioi) for the treatment of children less than 2 years of age with spinal muscular atrophy
Basel, August 6, 2019 – Today the FDA released a statement addressing data integrity issues with the Biologics License Application (BLA) for Zolgensma® (onasemnogene abeparvovec-xioi). First and foremost, we are fully confident in the safety, quality and efficacy of Zolgensma.
Toggle Summary AveXis Statement on Access to Zolgensma® (onasemnogene abeparvovec-xioi)
The FDA's May 2019 approval of Zolgensma ® , a gene therapy for spinal muscular atrophy (SMA) in pediatric patients less than 2 years of age, marked an important milestone within the SMA community. Zolgensma offers a new treatment option for children with SMA and their families.
AveXis Statement on Access to Zolgensma® (onasemnogene abeparvovec-xioi)
The FDA's May 2019 approval of Zolgensma ® , a gene therapy for spinal muscular atrophy (SMA) in pediatric patients less than 2 years of age, marked an important milestone within the SMA community. Zolgensma offers a new treatment option for children with SMA and their families.
Toggle Summary AveXis Announces Innovative Zolgensma® Gene Therapy Access Programs for US Payers and Families
One-time treatment with Zolgensma (onasemnogene abeparvovec-xioi) is designed to replace lifetime of chronic therapy for all pediatric patients with SMA   Annualized cost of Zolgensma is USD 425,000 per year for 5 years: 50% less than multiple established value-based pricing benchmarks including
AveXis Announces Innovative Zolgensma® Gene Therapy Access Programs for US Payers and Families
One-time treatment with Zolgensma (onasemnogene abeparvovec-xioi) is designed to replace lifetime of chronic therapy for all pediatric patients with SMA   Annualized cost of Zolgensma is USD 425,000 per year for 5 years: 50% less than multiple established value-based pricing benchmarks including
Toggle Summary AveXis receives FDA approval for Zolgensma®, the first and only gene therapy for pediatric patients with spinal muscular atrophy (SMA)
SMA is a rare genetic disease that leads to progressive muscle weakness, paralysis and, when left untreated in its most severe form, permanent ventilation or death for most patients by age 2 [1],[2]   Zolgensma (onasemnogene abeparvovec-xioi) is approved for the treatment of pediatric patients less
AveXis receives FDA approval for Zolgensma®, the first and only gene therapy for pediatric patients with spinal muscular atrophy (SMA)
SMA is a rare genetic disease that leads to progressive muscle weakness, paralysis and, when left untreated in its most severe form, permanent ventilation or death for most patients by age 2 [1],[2]   Zolgensma (onasemnogene abeparvovec-xioi) is approved for the treatment of pediatric patients less
Toggle Summary New AveXis data at AAN showed long-term durability of Zolgensma® in patients with spinal muscular atrophy (SMA) Type 1
Interim long-term follow-up data showed all enrolled Cohort 2 patients maintained motor function and milestones achieved during the Phase 1 START trial   Mean age of follow-up since dosing with Zolgensma ( onasemnogene abeparvovec-xioi; AVXS-101) was nearly four years, with some patients nearing
New AveXis data at AAN showed long-term durability of Zolgensma® in patients with spinal muscular atrophy (SMA) Type 1
Interim long-term follow-up data showed all enrolled Cohort 2 patients maintained motor function and milestones achieved during the Phase 1 START trial   Mean age of follow-up since dosing with Zolgensma ( onasemnogene abeparvovec-xioi; AVXS-101) was nearly four years, with some patients nearing